RxDoctor Payments DataLook up a doctor →

Kimberly Bridges, MD

Pulmonary Disease · Birmingham, ALNPI 1619317963

Payments from drug & device makers

$10,854in general payments, 2019–2025

Across 541 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$773
  • Regeneron Healthcare Solutions, Inc.$743
  • Mallinckrodt Hospital Products Inc.$730
  • Grifols USA, LLC$574
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$10,75499%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,854 in reported general payments places this provider in the 70th percentile of 215 pulmonary disease providers in Alabama.

See all pulmonary disease providers in Alabama

Medicare billing

Part B allowed, 2024
$92,961
Medicare patients
308
Services billed
996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aralast NpAlpha-1-Proteinase Inhibitor12$129,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$83,499
Breztri AerosphereBudesonide/Glycopyr/Formoterol116$81,065
Breo ElliptaFluticasone/Vilanterol29$21,362
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$17,735
Advair HfaFluticasone Propion/Salmeterol13$4,645
Albuterol Sulfate HfaAlbuterol Sulfate141$4,300
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,846
Montelukast Sodium102$1,286
Roflumilast16$855
Azithromycin52$541
Fluticasone Propionate15$312
Levocetirizine Dihydrochloride20$183
Prednisone45$101
Alprazolam13$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,803$122,597178 claims
AstraZenecaBreztri Aerosphere$1,162$81,065116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 215 pulmonary disease providers in Alabama.

Other pulmonary disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →